Trending...
- Team Crush Yard Wins Gold Medal at 2024 Joola Pickleball With Orlando Director of Pickleball
- Coastal Orthopedics announces new spine surgeon joining group
- Hayley Ross Endorses Former Opponent, Martin Karp for Miami-Dade School Board Dist 3
IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
POTOMAC, Md. - Floridant -- IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on The Floridant
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on The Floridant
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on The Floridant
- Osivette Brito, Former Pirate of Illegal TV Streaming, Faces Trouble UFC Gym License in Jeopardy
- Stay Connected During Hurricane Milton: Essential Satellite Solutions from Satellite Phone Store
- Florida: Governor Ron DeSantis Suspends Tolls To Assist Hurricane Milton Evacuations
- Berkshire Hathaway HomeServices FNR President Ann King receives 2024 Ultimate CEO Award
- As Hurricane Milton Approaches, Complete Sliding Doors & Windows Stands Ready to Help
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on The Floridant
- Florida: Governor Ron DeSantis Issues Updates on State Preparedness Efforts for Hurricane Milton
- Martial Arts Icon Cynthia Rothrock Premieres Her Latest Film Black Creek
- Vantiva and Harmonic Partner to Offer Service Providers Easy Transition from DOCSIS to Fiber-based PON Technologies
- Tommy Bohanon Foundation to host 5th Annual Softball Tournament and Toy Drive
- PSCO Florida: Your One-Stop Shop for Hurricane Season Sign Repair and Maintenance
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Contact
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Source: IGC PHARMA
Filed Under: Health
0 Comments
Latest on The Floridant
- The Magic Table by LG Lesmo: The Ultimate Space-Saving Solution
- Nails, Wax Eyebrow Threading, Hair Extensions, Spray Tans, Hair Stylists, and Hair Color Experts!
- Braswell Group Announces Speaker Lineup for 2024 Live 2 Lead Leadership Conference in Orland
- Ismael Cala Foundation and FICOP join forces to enhance the emotional education of young Hispanics USA - English USA - español
- Benchmark International Faciltd BT International Restaurant Distributors & Hart & Price Corporation
- Life Is Gouda Celebrates Grand Opening of Brick-and-Mortar Location at Life Essentials Refillery
- ProtectVirginia Petitions Virginia Dept of Environmental Quality for Cruise Ship Regulations
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Real Estate Expert in Central Florida Advises Buyers on Timing the Market: Buy Now or Wait?
- Florida: MEMORANDUM: EXECUTIVE ORDERS 24-212 & 24-213 and DBPR ORDER 2024-9
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- Better Together receives $15,000 grant from the Collier Community Foundation
- Brite Homes Wins Overall Diamond Award at Space Coast Parade of Homes in Palm Bay, Florida
- Greater Fort Myers Chamber CEO Robert Goltz receives service award
- Sequentex Partners with Axxess Networks to Bring Enhanced Communications Solutions to South Florida
- Team Crush Yard Wins Gold Medal at 2024 Joola Pickleball With Orlando Director of Pickleball
- Groundbreaking Ceremony Marks New Growth for Luxury Yacht Builders in Florida
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- Florida: Governor Ron DeSantis Makes One Judicial Appointment